Exelixis

Historical price data

Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.

Dual-platform strategy combining deep expertise in small molecule kinase inhibitor discovery with an emerging internal biotherapeutics engine focused on modalities like bispecific antibodies and antibody-drug conjugates.